Clinician-reviewed CDS · Browser-local · No identifiers · Source-linkedRead more…
This tool is educational and informational. It does not replace clinical judgment. Verify trial populations, sICH definitions, BP target ranges, and post-treatment monitoring against the cited source before acting.
Not prospectively validated. No clinical tool replaces bedside assessment.
This tool qualifies as non-device clinical decision support under the January 2026 FDA CDS guidance (21st Century Cures Act §3060). It does not acquire or analyze patient data, it displays the basis for its recommendations, it enables independent clinician review, and it is intended for use by trained healthcare professionals.
This runs entirely in your browser; we store nothing. Even so, enter only clinical data (age, vitals, exam findings) -- not names, MRNs, or other identifiers.
Tarvinder Singh, MD -- Vascular Neurologist. March 2026.
Stroke
Hyperacute reperfusion decisions, post-treatment monitoring, hemorrhage management, TIA triage, and mechanism-specific secondary prevention.
Acute Ischemic Stroke
IVT and EVT eligibility by time window, imaging, and contraindication profile. Matches against AHA/ASA 2026 guidelines and trial populations.
Use when Acute stroke code with possible large vessel occlusion. Determines IVT and EVT eligibility in real time.
Open →
Post-IVT Care
First-24-hour monitoring after IV thrombolysis: BP targets, sICH recognition, imaging timing, and rescue protocols
Use when After IVT administration. Guides BP checks, sICH vigilance, and next-day planning.
Open →
Post-EVT Care
First-24-hour monitoring after thrombectomy: BP by reperfusion grade, groin-site care, and contrast nephropathy prevention
Use when After thrombectomy. Guides BP by reperfusion grade and post-procedural monitoring.
Open →
TIA Rapid Assessment
Risk stratification, DAPT timing by CHANCE/POINT/THALES evidence, and urgent workup priorities
Use when Transient neurologic deficit resolved on arrival. Stratifies risk and guides DAPT timing.
Open →
Secondary Prevention
Mechanism-specific antithrombotic selection, anticoagulation timing, and PFO/cryptogenic stroke pathway
Use when Stroke mechanism established. Selects antithrombotic strategy by etiology.
Open →
ICH Management
ICH score, BP targets, anticoagulant reversal, seizure management, and surgical decision cues
Use when Intracerebral hemorrhage confirmed on imaging. Guides severity scoring, reversal, and BP management.
Open →
Pediatric Stroke
Pediatric IVT and EVT review with age-specific dosing, etiology considerations, and safety cautions
Use when Pediatric acute ischemic stroke (age 2-17). Weight-based dosing with etiology-specific pathways.
Open →
Recently updated
TNK effect size scatter chart2026-03-22
New SVG scatter plot on /stroke/evidence showing absolute risk reduction vs. year for 13 TNK trials. NI cluster near zero, extended-window trials at +8–10%, negative trials below. Interactive dots surface trial details and PubMed links.
HOPE trial distribution data verified and corrected2026-03-22
HOPE trial (PMID 40773205) distribution data verified against JAMA Table 1. Ischemic core median corrected 8→13 mL, IQR [2,22]→[4,28]. NIHSS IQR upper bound corrected 16→15. SELECT2, ANGEL-ASPECT, RESCUE-Japan LIMIT outcomes confirmed; demographics flagged as needing full-text verification.
Dropdown disambiguation and hospital graceful degradation2026-03-22
Quick-entry and full-form dropdowns now distinguish "not assessed" from "no occlusion" and "unknown." JsRequired component provides static fallback link to Evidence Library for hospital environments with JS restrictions. Angioedema protocol ranitidine details streamlined.
Mobile-first audit: font floors and touch targets2026-03-22
Bumped 8 unreadable text-[8px] labels to text-[10px] across AIS timeline, anatomy SVG, and guideline cards. Enlarged age/NIHSS quick buttons to 44px touch targets. TNK dosing table overflow-x-auto wrapper added. BP section padding reduced for 375px screens.
AI Pulse citation compliance pass2026-03-22
OPTION trial numbers corrected (N=570, RR 1.28, P=0.02 — previously wrong). LAIS conference-abstract outcome numbers stripped pending peer-reviewed publication. FDA guidance linked to FDA.gov source. Two vendor-blog entries removed. Citation hierarchy enforced in file header.
Workflow
Start with acute ischemic stroke for IVT/EVT eligibility. Move to post-treatment care after reperfusion. Use ICH for hemorrhage management, TIA for rapid risk stratification, and secondary prevention for mechanism-specific antithrombotic selection.